Navigation Links
Novo Nordisk Expands U.S. Headquarters in New Jersey

PRINCETON, N.J., March 5 /PRNewswire-FirstCall/ -- Novo Nordisk, a healthcare company with an 85-year history of innovation and achievement in diabetes care, today announced plans to expand its U.S. headquarters in Princeton to accommodate future growth. In the past five years, the company has experienced a 150 percent increase in employees at its U.S. headquarters.

The new building will have the capacity for more than 400 employees and feature an in-house training facility capable of training 100 employees simultaneously.

"Diabetes in the U.S. is an unfortunate and growing epidemic and we've had to expand to meet that challenge," said Jerzy Gruhn, president of Novo Nordisk, Inc. "The expansion of our headquarters will provide our team of talented and dedicated employees a modern, spacious facility that will enable them to continue changing diabetes and realize our vision of defeating the disease.

"We consider the state of New Jersey and our local community key contributors to our vision, as they have been exemplary partners and have supported and encouraged Novo Nordisk's growth in the area."

"New Jersey has long been a leader in the global healthcare marketplace," said Governor Jon S. Corzine. "Our prime location, robust workforce and high quality of life have been contributing factors to attracting some of the world's major pharmaceutical companies to the state. We are indeed pleased that Novo Nordisk will continue its commitment here by extending its leadership in diabetes care with a larger presence in New Jersey."

In keeping with the company's Triple Bottom Line philosophy of economic vitality and social and environmental responsibility, the $20-million facility is expected to acquire Leadership in Energy and Environmental Design (LEED) certification through a unique, sustainable design. The LEED Green Building Rating System(TM) is the nationally accepted benchmark for the design, construction, and operation of high performance, environmentally friendly and healthy commercial buildings.

"A good corporate and community neighbor like Novo Nordisk in the township is the kind of partnership that attracts the same, making our community even stronger," said Plainsboro township mayor, Peter Cantu.

Staying true to the company's heritage, the new facility will embody the principles of Danish design -- functionality, innovation, openness, quality and aesthetics. The interior design will encourage the use of the exterior daylight and feature "smart lighting" that will automatically dim and adjust to promote a whole-building approach to sustainability. In addition the construction, furniture and interior finishes use environmentally friendly materials that are both made from recycled materials and that are also ultimately recyclable.

Novo Nordisk plans to begin occupying the new campus located at 1100 College Road, in the spring. The lease is for 15 years and the facility is the first of five, five-story buildings to be completed in Princeton Corporate Campus, an 800,000-square-foot master-planned office development located in Plainsboro.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 85-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit; for United States information, visit

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
2. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
3. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
4. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
5. Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide
6. ATS Medical Expands Open Pivot Heart Valve Offerings
7. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
8. BioLife Solutions Expands Scientific Advisory Board
9. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
10. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
11. Pharsight Expands Strategic Consulting Services Team
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
Breaking Biology News(10 mins):